1. Home
  2. PSFE vs TVTX Comparison

PSFE vs TVTX Comparison

Compare PSFE & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysafe Limited

PSFE

Paysafe Limited

HOLD

Current Price

$6.99

Market Cap

390.7M

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$28.06

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSFE
TVTX
Founded
1996
N/A
Country
United Kingdom
United States
Employees
2900
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.7M
3.3B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
PSFE
TVTX
Price
$6.99
$28.06
Analyst Decision
Hold
Strong Buy
Analyst Count
5
13
Target Price
$10.15
$36.25
AVG Volume (30 Days)
436.9K
1.2M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.89
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.50
$44.62
Revenue Next Year
$5.85
$32.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.95
$12.91
52 Week High
$18.15
$42.13

Technical Indicators

Market Signals
Indicator
PSFE
TVTX
Relative Strength Index (RSI) 49.23 44.31
Support Level $6.58 $26.72
Resistance Level $7.62 $31.47
Average True Range (ATR) 0.43 1.18
MACD 0.04 0.01
Stochastic Oscillator 52.17 33.99

Price Performance

Historical Comparison
PSFE
TVTX

About PSFE Paysafe Limited

Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

Share on Social Networks: